“teva-pharmaceutical” Archives

in
Entry Author Date Location
Biotech Roundup: FDA Culpa, Tricida Trips, Freenome’s Funding & More 08/28/20 National
Ventus Launches With $60M to Shine Light on Innate Immune System Drugs 05/06/20 Boston
Lundbeck’s Alder Bio Bet Pays Off With FDA Approval of Migraine Drug 02/23/20 National
Daré to Add Microchip-Based Birth Control to Women’s Health Portfolio 11/15/19 San Diego
Bio Roundup: Feds Sue Gilead, Biogen Eyes China, CRISPR’d Kidneys & More 11/08/19 National
Bio Roundup: Biogen’s Reversal, FDA Moves Fast, a CF Cocktail & More 10/25/19 National
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More 10/18/19 National
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades 10/11/19 Indiana
Lundbeck Paying Nearly $2B for Alder to Follow Migraine Rivals to Market 09/16/19 National
Eli Lilly’s Approved Migraine Drug Wins FDA OK for Cluster Headache 06/04/19 Indiana
Bio Roundup: Opioids in Court, IPO Parade, Brain Cancer Bet & More 05/31/19 National
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More 05/17/19 National
SMA, Migraine Data Lead Neuro Highlights from AAN Meeting 05/07/19 National
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments 05/03/19 National
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More 04/26/19 National
Teva’s Approved Migraine Drug Fails Again to Blunt Rarer Headache 04/23/19 New York
Bio Roundup: Gottlieb’s Goodbye, AACR Recap, Migraine Drug Fight & More 04/05/19 National
Roche Gains Place in NASH Race with Purchase of Jecure Therapeutics 11/27/18 San Francisco
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More 10/26/18 National
89Bio Joins NASH Chase with a Teva Drug and $60M in Funding 10/25/18 San Francisco
Bio Roundup: Prices on TV, Novartis Hearts Radio, Warp Drive’s End 10/19/18 National
Report: Express Scripts Shuts Out Teva Migraine Drug, Prefers Rivals 10/17/18 National
Bio Roundup: Nobel Prizes, Duchenne Steps, Guardant’s IPO & More 10/05/18 National
Eli Lilly Migraine Drug Approved, the Third in New Class of Medicines 09/28/18 Indiana
Teva Wins FDA Nod for Migraine Drug, Sets Price in Line with Amgen’s 09/14/18 National
Bio Roundup: A Gene Editing 1st, China Rises, Schenkein Steps Away 09/07/18 National
Bio Roundup: EpiPen Shortage, Bluebird’s Bet, Biotech IPOs & More 08/24/18 National
Bio Roundup: Big Approvals, ICER Influence, Drug-Price Pushback & More 08/17/18 National
Pain Drug Race Continues as Regeneron Posts Early Phase 3 Results 08/16/18 New York
Lundbeck Reaches Across Atlantic, Picks Dunsire for CEO Post 07/02/18 Boston
Page 1 of 3 next page »